Biotech stocks in 2026 revealed important trends when viewed through the BioWorld Stock Indicator and Nasdaq Biotech Index. This analysis compares the sector’s performance throughout the year, showcasing areas of growth and fluctuation.

Castle Biosciences (NASDAQ: CSTL) received a resounding vote of confidence this week when Canaccord Genuity Group reaffirmed its “buy” rating. The firm’s price objective of $37.00 points to a potential 61.29% upside for the company’s shares.

William Blair has lowered its third-quarter 2025 earnings forecast for Jasper Therapeutics to a loss of $0.75 per share, according to an analyst note issued on August 14. The deeper-than-expected projection, reported by Defenseworld.net, signals mounting challenges for the California-based biotech firm.